EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor

Ryuzo Hanada, Toru Takenaka

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1504 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Ryuzo Hanada und 1 weiteren Autor:innen. Beteiligte Einrichtung: SOUSEIKAI Sumida Hospital, Tokyo, Japan. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon‐14 ( 14 C)‐labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431). After administering a single oral dose of [ 14 C]pizuglanstat solution containing 400 mg of pizuglanstat and 1 megabecquerel of radioactivity to 6 healthy men (median age, 26 years), pizuglanstat in plasma reached a maximal concentration after a median of 0.5 hour and declined with a geometric mean half‐life of 7.7 hours. Pizuglanstat and its metabolites were primarily excreted via the fecal route; on average, 66.1% of administered radioactivity was excreted in feces after 168 hours, compared with 32.2% excreted in urine. Pizuglanstat was mostly present as the unchanged parent molecule in plasma, urine, and feces, while the sulfate conjugate of hydroxyl pizuglanstat was the major metabolite in each sample type. Two adverse drug reactions of urticaria were reported in 2 participants (33.3%); both events were nonsevere and manageable with treatment, and no other clinically significant safety events were observed. Overall, this study provides important pharmacokinetic, mass balance, and safety data to support the development of pizuglanstat as a new treatment for Duchenne muscular dystrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansMaleAdultYoung AdultHalf-LifeAdministration, OralHealthy VolunteersFecesCarbon Radioisotopes

Stichwörter der Autor:innen

Duchenne muscular dystrophyTAS‐205mass balance studypharmacokineticspizuglanstat

Substanzen

Carbon Radioisotopes

Autor:innen und Institutionen

  • SOUSEIKAI Sumida Hospital, Tokyo, Japan.
  • Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.

Zitieren

APA

Hanada, R., & Takenaka, T. (2025). Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1504

Vancouver

Hanada R, Takenaka T. Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1504

BibTeX
@article{Hanada2025,
  author = {Hanada, Ryuzo and Takenaka, Toru},
  title = {Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1504}
}
Kostenlos starten →